Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 5:24 p.m.

    📋 EyePoint Pharmaceuticals, Inc. (EYPT) - Financial Results

    Filing Date: 2022-08-03

    Accepted: 2022-08-03 07:07:00

    Event Type: Financial Results

    Event Details:

    EyePoint Pharmaceuticals Inc (EYPT) Reports Q3 2022 Financial Results EyePoint Pharmaceuticals Inc (EYPT) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: 14070
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 82134
      • expected in the second half of 2023
      • targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Operating Expenses Loss From Operations 10.98K 37.50K $-26.52K -70.72%
    Other Income Expense Interest Expense 1.38K 1.75K $-369.00 -21.15%
    Other Income Expense Total Other Income Expense 969.00 2.88K $-1.91K -66.37%
    Other Income Expense Net Loss 10.01K 40.38K $-30.37K -75.21%
    Other Income Expense Net Loss Per Share 0.35 1.08 $-0.73 -67.59%
    Current Assets Prepaid Expenses Other Current Assets 8.85K 4.22K $4.63K +109.89%
    Current Assets Operating Lease Right Of Use Assets 4.79K 2.25K $2.54K +112.57%
    Current Assets Intangible Assets Net 21.52K 22.75K $-1.23K -5.41%
    Current Assets Other Assets 1.26K 626.00 $635.00 +101.44%
    Current Liabilities Other Long Term Liabilities 600.00 2.35K $-1.75K -74.49%
    Revenue 11.56K 9.01K $2.55K +28.31%
    Loss from Operations 19.22K 10.98K $8.24K +75.03%
    Other Income, Net 362.00 280.00 $82.00 +29.29%
    Interest Expense 552.00 1.38K $-824.00 -59.88%
    Total Other Income/(Expense) 190.00 969.00 $-779.00 -80.39%
    Net Loss 19.41K 10.01K $9.40K +93.87%
    Prepaid Expenses and Other Current Assets 8.85K 4.22K $4.63K +109.89%
    Intangible Assets, Net 21.52K 22.75K $-1.23K -5.41%
    Other Assets 1.26K 626.00 $635.00 +101.44%
    Accounts Payable 21.37K 21.81K $-437.00 -2.00%
    Operating Lease Liabilities 4.83K 1.86K $2.97K +159.46%

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: EyePoint Pharmaceuticals Inc
    • CIK: 0001314102
    • Ticker Symbol: EYPT
    • Period End Date: 2022-08-03
    • Document Type: 8-K

Search

News categories